Tag: company

Press Release

Highlights

A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort.

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the “Western Asset US Core Bond Fund” mutual fund classes – Class I (ticker: “WATFX”), Class A (ticker: “WABAX”), Class C (ticker: “WABCX”), Class FI (ticker: “WAPIX”), Class IS (ticker: “WACSX”), and Class R (ticker: “WABRX”) – and the “Western Asset Core Plus Bond Fund” mutual fund classes – Class A (ticker: “WAPAX”), Class C (ticker: “WAPCX”), Class C1 (ticker: “LWCPX”), Class FI (ticker: “WACIX”), Class R (ticker: “WAPRX”), Class I (ticker: “WACPX”), Class IS (ticker: “WAPSX”) between January 1, 2021 and October 31, 2023, inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline.

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of shares of the Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the “Fund”) (tickers: RMJAX, RMHVX, RMHIX), between May 5, 2023 and June 12, 2025, inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline. The Fund is a mutual fund within defendant James Alpha Funds Trust’s series of mutual funds (which does business as Easterly Funds Trust).

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST.

Increased search volume around clean-label metabolic supplements — including queries like “ProZenith complaints” — reflects a wider shift in how consumers are navigating stimulant-free wellness solutions in North America.

More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First Joint Hydration Formulas Like Simple Promises' XentaFlex